Rege Nephro Co., Ltd.

Rege Nephro is pre-clinical stage company developing a allogenic cell therapy by human iPS cell-derived nephron progenitor cells (iNPCs) for chronic kidney disease (CKD). iNPCs are differentiated from iPS cells and originally created by Dr. Osafune, a professor of CiRA, Center for iPS Cell Research and Application, Kyoto University. iNPCs are effective for the treatment of pre-clinical CKD models when injected into the kidney. The manufacturing process has been established and the therapy is currently undergoing pre-clinical studies. We are aiming to begin clinical trials in the coming year.
Another pipeline is a small molecule drug for ADPKD, discovered from a disease model reconstituted from patient-derived iPS cells invented from Osafune Lab. Currently, a Phase II clinical trial is planned in this year.
Rege Nephro has been funded by top-tier Japanese venture capital firms and is now seeking business partners for these pipelines and new investors.